0001193125-22-016547.txt : 20220125 0001193125-22-016547.hdr.sgml : 20220125 20220125080103 ACCESSION NUMBER: 0001193125-22-016547 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220119 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220125 DATE AS OF CHANGE: 20220125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001783183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824151574 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39094 FILM NUMBER: 22551150 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (877) 742-8466 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 8-K 1 d263259d8k.htm 8-K 8-K
false 0001783183 0001783183 2022-01-19 2022-01-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 19, 2022

 

 

PHATHOM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39094   82-4151574

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

100 Campus Drive, Suite 102

Florham Park, New Jersey 07932

(Address of principal executive offices) (Zip Code)

(877) 742-8466

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   PHAT   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 19, 2022, the compensation committee (the “Compensation Committee”) of the board of directors of Phathom Pharmaceuticals, Inc. (the “Company”) adopted a form of restricted stock unit award agreement (the “Form of RSU Award Agreement”) to be used for the grant of restricted stock units (“RSUs”) pursuant to the terms of the Company’s 2019 Incentive Award Plan (the “Plan”).

The Form of RSU Award Agreement (a) provides for the grant of RSUs to eligible participants under the Plan, which RSUs may, among other things, be subject to (i) vesting in accordance with the vesting schedule provided in the applicable grant notice and (ii) certain transfer restrictions, and (b) authorizes the Company to cause shares to be sold on the participant’s account to cover applicable withholding taxes due upon vesting of the shares underlying the RSUs.

The foregoing description of the Form of RSU Award Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Form of RSU Award Agreement, which is included as Exhibit 10.1 to this Current Report and incorporated herein by reference.

In addition, on January 19, 2022, the Compensation Committee awarded RSUs to the following executive officers under the Plan: 41,250 RSUs awarded to Terrie Curran, 19,500 RSUs awarded to Azmi Nabulsi and 6,000 RSUs awarded to Anthony Guzzo. Each RSU represents the right to receive one share of the Company’s common stock, $0.0001 par value per share, upon vesting. The RSUs vest in three equal annual installments, subject to the individual’s continued service to the Company through the applicable vesting date, and are subject to the terms and conditions of the Company’s Form of RSU Award Agreement under the Plan.

 

Item 9.01

Financial Statements and Exhibits.

 

  (d)

Exhibits.

 

Exhibit
No.		   

Description

10.1    Form of Restricted Stock Unit Agreement under the 2019 Incentive Award Plan.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PHATHOM PHARMACEUTICALS, INC.
Date:January 25, 2022     By:  

/s/ Larry Miller

     

Larry Miller

General Counsel and Secretary

 EX-10.1 2 d263259dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

 

PHATHOM PHARMACEUTICALS, INC.

 

2019 INCENTIVE AWARD PLAN

 

RESTRICTED STOCK UNIT GRANT NOTICE

Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2019 Incentive Award Plan (as amended from time to time, the “Plan”) of Phathom Pharmaceuticals, Inc. (the “Company”).

The Company hereby grants to the participant listed below (“Participant”) the Restricted Stock Units described in this Grant Notice (the “RSUs”), subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement attached hereto as Exhibit A (the “Agreement”), both of which are incorporated into this Grant Notice by reference.

 

Participant:    [Insert Participant Name]
Grant Date:    [Insert Grant Date]
Number of RSUs:    [Insert Number of RSUs]
Vesting Commencement Date:    [Insert Vesting Commencement Date]
Vesting Schedule:    Subject to the Participant’s continued service, one-third (1/3rd) of the RSUs shall vest on each of the first, second and third anniversaries of the Vesting Commencement Date.

By electronically accepting this document, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant has been provided with a copy or electronic access to a copy of the prospectus for the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.

 

PHATHOM PHARMACEUTICALS, INC.     PARTICIPANT
By:  

 

     By:  

 

Print Name:  

 

     Print Name:  

 

Title:  

 

      

EXHIBIT A

RESTRICTED STOCK UNIT AGREEMENT

Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.

ARTICLE I.

GENERAL

1.1 Award of RSUs. The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the “Grant Date”). Each RSU represents the right to receive one Share, as set forth in this Agreement. Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested.

1.2 Incorporation of Terms of Plan. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.

1.3 Unsecured Promise. The RSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company’s general assets.

ARTICLE II.

VESTING; FORFEITURE AND SETTLEMENT

2.1 Vesting; Forfeiture. The RSUs will vest according to the vesting schedule in the Grant Notice (the “Vesting Schedule”), except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant’s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. Unless and until the RSUs have vested in accordance with the Vesting Schedule set forth in the Grant Notice, Participant will have no right to any distribution with respect to such RSUs.

2.2 Settlement.

(a) RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60) days after the applicable vesting date. Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A.

(b) All distributions shall be made by the Company in the form of whole shares of Common Stock.

(c) Neither the time nor form of distribution of Shares with respect to the RSUs may be changed, except as may be permitted by the Administrator in accordance with the Plan and Section 409A of the Code and the Treasury Regulations thereunder.

 

A-1

ARTICLE III.

TAXATION AND TAX WITHHOLDING

3.1 Representation. Participant represents to the Company that Participant has reviewed with Participant’s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.

3.2 Tax Withholding.

(a) The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the RSUs to Participant or his or her legal representative unless and until Participant or his or her legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes applicable with respect to the taxable income of Participant resulting from the vesting or settlement of the RSUs, the distribution of the Shares issuable with respect thereto, or any other taxable event related to the RSUs (the “Tax Withholding Obligation”).

(b) Participant may elect to satisfy the Tax Withholding Obligation as provided in Section 9.5 of the Plan. Unless Participant elects to satisfy the Tax Withholding Obligation by one of the means described in Section 9.5 of the Plan, the Company has the right and option, but not the obligation, to treat Participant’s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the RSUs as Participant’s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award.

(a) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the RSUs. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs to reduce or eliminate Participant’s tax liability.

ARTICLE IV.

OTHER PROVISIONS

4.1 Award Not Transferable. Without limiting the generality of any other provision hereof, the Award shall be subject to the restrictions on transferability set forth in Section 9.1 of the Plan.

4.2 Adjustments. Participant acknowledges that the RSUs and the Shares subject to the RSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan.

4.3 Notices. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company’s Secretary at the Company’s principal office or the Secretary’s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the Designated Beneficiary) at Participant’s last known mailing address, email address or facsimile number in the Company’s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.

 

A-2

4.4 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.

4.5 Conformity to Securities Laws. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.

4.6 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

4.7 Limitations Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.

4.8 Entire Agreement. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.

4.9 Agreement Severable. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.

4.10 Limitation on Participant’s Rights. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the RSUs, as and when settled pursuant to the terms of this Agreement.

4.11 Not a Contract of Employment. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.

4.12 Counterparts. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.

 

A-3

4.12 Section 409A.

(a) Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the Plan, this Agreement and the Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, “Section 409A”). The Administrator may, in its discretion, adopt such amendments to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate to comply with the requirements of Section 409A.

(b) This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the Shares issuable pursuant to the RSUs hereunder shall be distributed to Participant no later than the later of: (A) the fifteenth (15th) day of the third month following Participant’s first taxable year in which such RSUs are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such RSUs are no longer subject to substantial risk of forfeiture, as determined in accordance with Section 409A and any Treasury Regulations and other guidance issued thereunder.

4.13 Governing Law. The provisions of the Plan and all Awards made thereunder, including the RSUs, shall be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding choice-of-law principles of the law of any state that would require the application of the laws of a jurisdiction other than such state.

* * * * *

 

A-4

EX-101.SCH 3 phat-20220119.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 phat-20220119_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 phat-20220119_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 19, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001783183
Document Type 8-K
Document Period End Date Jan. 19, 2022
Entity Registrant Name PHATHOM PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39094
Entity Tax Identification Number 82-4151574
Entity Address, Address Line One 100 Campus Drive
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code (877)
Local Phone Number 742-8466
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol PHAT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 7 d263259d8k_htm.xml IDEA: XBRL DOCUMENT 0001783183 2022-01-19 2022-01-19 false 0001783183 8-K 2022-01-19 PHATHOM PHARMACEUTICALS, INC. DE 001-39094 82-4151574 100 Campus Drive Suite 102 Florham Park NJ 07932 (877) 742-8466 false false false false Common Stock, par value $0.0001 per share PHAT NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d263259d8k.htm d263259dex101.htm phat-20220119.xsd phat-20220119_lab.xml phat-20220119_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d263259d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d263259d8k.htm" ] }, "labelLink": { "local": [ "phat-20220119_lab.xml" ] }, "presentationLink": { "local": [ "phat-20220119_pre.xml" ] }, "schema": { "local": [ "phat-20220119.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "phat", "nsuri": "http://www.phathompharma.com/20220119", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d263259d8k.htm", "contextRef": "duration_2022-01-19_to_2022-01-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d263259d8k.htm", "contextRef": "duration_2022-01-19_to_2022-01-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.phathompharma.com//20220119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-22-016547-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-016547-xbrl.zip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